TWI799849B - 治療或預防偏頭痛之方法 - Google Patents

治療或預防偏頭痛之方法 Download PDF

Info

Publication number
TWI799849B
TWI799849B TW110115984A TW110115984A TWI799849B TW I799849 B TWI799849 B TW I799849B TW 110115984 A TW110115984 A TW 110115984A TW 110115984 A TW110115984 A TW 110115984A TW I799849 B TWI799849 B TW I799849B
Authority
TW
Taiwan
Prior art keywords
treating
methods
migraine headache
preventing migraine
preventing
Prior art date
Application number
TW110115984A
Other languages
English (en)
Other versions
TW202130369A (zh
Inventor
孫宏
艾德瓦多 杜納耶維
羅伯特 蘭茲
蓋伯爾 法蓋斯
Original Assignee
美商安美基公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安美基公司 filed Critical 美商安美基公司
Publication of TW202130369A publication Critical patent/TW202130369A/zh
Application granted granted Critical
Publication of TWI799849B publication Critical patent/TWI799849B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)
TW110115984A 2015-04-24 2015-08-07 治療或預防偏頭痛之方法 TWI799849B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562152708P 2015-04-24 2015-04-24
US62/152,708 2015-04-24

Publications (2)

Publication Number Publication Date
TW202130369A TW202130369A (zh) 2021-08-16
TWI799849B true TWI799849B (zh) 2023-04-21

Family

ID=53969433

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110115984A TWI799849B (zh) 2015-04-24 2015-08-07 治療或預防偏頭痛之方法
TW104125845A TWI728953B (zh) 2015-04-24 2015-08-07 治療或預防偏頭痛之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW104125845A TWI728953B (zh) 2015-04-24 2015-08-07 治療或預防偏頭痛之方法

Country Status (30)

Country Link
US (3) US10259877B2 (zh)
EP (2) EP3285803B1 (zh)
JP (4) JP6392471B2 (zh)
KR (1) KR102464415B1 (zh)
CN (2) CN113908268A (zh)
AU (2) AU2015392215B2 (zh)
BR (1) BR112017022772A2 (zh)
CA (1) CA2984254C (zh)
CL (1) CL2017002686A1 (zh)
CY (1) CY1123211T1 (zh)
DK (1) DK3285803T3 (zh)
ES (1) ES2771925T3 (zh)
HK (1) HK1250914A1 (zh)
HR (1) HRP20200056T1 (zh)
HU (1) HUE048528T2 (zh)
IL (2) IL255114B (zh)
JO (2) JOP20200116A1 (zh)
LT (1) LT3285803T (zh)
MA (2) MA51815A (zh)
MX (2) MX2017013627A (zh)
PH (1) PH12017501934A1 (zh)
PL (1) PL3285803T3 (zh)
PT (1) PT3285803T (zh)
RS (1) RS59912B1 (zh)
RU (1) RU2707745C2 (zh)
SG (2) SG10202004282RA (zh)
SI (1) SI3285803T1 (zh)
TW (2) TWI799849B (zh)
WO (1) WO2016171742A1 (zh)
ZA (1) ZA201707179B (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US9896502B2 (en) 2014-03-21 2018-02-20 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
KR20190066607A (ko) 2016-09-23 2019-06-13 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
US20190071490A1 (en) 2017-03-02 2019-03-07 Beth Israel Deaconess Medical Center, Inc. Preventing Post-Ictal Headaches
WO2019055399A1 (en) * 2017-09-12 2019-03-21 Igc Bio, Inc. ANTI-VEGF ANTIBODIES
TWI831762B (zh) 2018-01-12 2024-02-11 美商安進公司 Pac1抗體及其用途
JP2021519790A (ja) * 2018-04-02 2021-08-12 アムジェン インコーポレイテッド エレヌマブ組成物及びその使用
AU2019299676A1 (en) 2018-07-05 2021-01-28 Allergan Pharmaceuticals International Limited Combination therapy with CGRP antagonists and Clostridial derivatives
MX2021008267A (es) 2019-01-08 2021-08-05 H Lundbeck As Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anti-cgrp.
SG11202110637RA (en) * 2019-05-02 2021-10-28 H Lundbeck As Treatment of headache using anti-cgrp antibodies
US20210130445A1 (en) 2019-07-05 2021-05-06 Allergan Pharmaceuticals International Limited CGRP Antagonists and Botulinum Toxins for the Treatment of Inflammatory and Neurologic Disorders
WO2021005494A1 (en) 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of neuropsychiatric and neurological disorders
WO2021005497A1 (en) 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders
US11607395B2 (en) * 2019-12-18 2023-03-21 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
KR20230157986A (ko) 2021-03-02 2023-11-17 체게에르페 다이어그노스틱스 게엠베하 편투통 발생의 치료 및/또는 저감
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
EP0590076A4 (en) 1991-06-14 1997-02-12 Dnx Corp Production of human hemoglobin in transgenic pigs
WO1993001227A1 (en) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
WO1993019180A1 (en) 1992-03-17 1993-09-30 Ciba-Geigy Ag Genetically engineered antibodies
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
JPH10504457A (ja) 1994-08-16 1998-05-06 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド カルシトニンレセプター
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU6596096A (en) 1996-07-23 1998-02-10 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
FR2821080B1 (fr) 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
ATE453661T1 (de) 2001-09-27 2010-01-15 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
KR101070213B1 (ko) 2002-08-12 2011-10-06 액타비스 그룹 에이취에프. 건선 치료를 위한 ｃｇｒｐ 안타고니스트 화합물의 용도
US20040176577A1 (en) 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
AR046787A1 (es) 2003-12-05 2005-12-21 Bristol Myers Squibb Co Agentes antimigrana heterociclicos
CN1961000B (zh) 2004-02-11 2011-05-04 安米林药品公司 具有可选择特性的杂合多肽
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
US7973140B2 (en) 2004-12-21 2011-07-05 Medimmune Limited Antibodies directed to angiopoietin-2 and uses thereof
DE102004063753A1 (de) 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
CN101232897A (zh) 2005-06-16 2008-07-30 新藤隆行 含有肾上腺髓质素作为有效成分的血管生成剂
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
CN101309704B (zh) * 2005-11-14 2012-10-10 礼纳特神经***科学公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
JP2009515973A (ja) 2005-11-18 2009-04-16 メルク エンド カムパニー インコーポレーテッド スピロラクタム三環式ｃｇｒｐ受容体アンタゴニスト
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
CA2650932C (en) 2006-05-09 2013-01-22 Merck & Co., Inc. Substituted spirocyclic cgrp receptor antagonists
AU2007348941B2 (en) 2006-08-03 2011-08-04 Medimmune Limited Antibodies directed to alphaVbeta6 and uses thereof
US8372859B2 (en) 2007-04-11 2013-02-12 Merck, Sharp & Dohme Corp. CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
EP2146712A4 (en) 2007-04-16 2010-10-13 Merck Sharp & Dohme ANTAGONISTS OF ARYL HETEROCYCLIC CGRP RECEPTORS
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
KR101304085B1 (ko) 2008-03-04 2013-09-05 라브리스 바이올로직스 인코포레이티드 염증성 통증의 치료 방법
AU2009257733A1 (en) 2008-06-12 2009-12-17 Merck Sharp & Dohme Corp. Branched 3- and 6-substituted quinolines as CGRP receptor antagonists
FR2934597B1 (fr) 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
AU2009293471A1 (en) 2008-09-18 2010-03-25 Merck Sharp & Dohme Corp. Bicyclic dihydroimidazolone CGRP receptor antagonists
JP2012504625A (ja) 2008-10-03 2012-02-23 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体アンタゴニスト
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
AU2010288194B2 (en) 2009-08-28 2013-08-29 Teva Pharmaceuticals International Gmbh Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
AR081434A1 (es) 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
JOP20190250A1 (ar) * 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AU2012258976B8 (en) * 2011-05-20 2017-07-20 H. Lundbeck A/S Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
HUE055505T2 (hu) 2011-05-20 2021-11-29 H Lundbeck As Anti-CGRP készítmények és alkalmazásuk
DK2709663T3 (da) * 2011-05-20 2019-05-20 Alderbio Holdings Llc Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere
ES2770976T3 (es) 2013-03-15 2020-07-06 Amgen Inc Anticuerpos PAC1 humanos
US9896502B2 (en) 2014-03-21 2018-02-20 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AU2015318008B2 (en) * 2014-09-15 2021-05-20 Amgen Inc. Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof

Also Published As

Publication number Publication date
EP3653225A1 (en) 2020-05-20
WO2016171742A1 (en) 2016-10-27
CN108156814A (zh) 2018-06-12
AU2015392215A1 (en) 2017-11-09
US20190256607A1 (en) 2019-08-22
IL255114A0 (en) 2017-12-31
PL3285803T3 (pl) 2020-06-01
RU2707745C2 (ru) 2019-11-29
JP2019001800A (ja) 2019-01-10
TW201637667A (zh) 2016-11-01
MX2017013627A (es) 2018-07-06
MX2021013327A (es) 2021-11-17
AU2022204866A1 (en) 2022-08-18
HRP20200056T1 (hr) 2020-04-03
JP6392471B2 (ja) 2018-09-19
SG11201708607WA (en) 2017-11-29
IL291153B2 (en) 2023-06-01
TW202130369A (zh) 2021-08-16
JP2018513871A (ja) 2018-05-31
US20230020514A1 (en) 2023-01-19
TWI728953B (zh) 2021-06-01
CL2017002686A1 (es) 2018-05-11
MA41932B1 (fr) 2020-04-30
JP6707590B2 (ja) 2020-06-10
DK3285803T3 (da) 2020-02-17
RU2017140789A (ru) 2019-05-24
US10259877B2 (en) 2019-04-16
PH12017501934A1 (en) 2018-03-19
CA2984254C (en) 2019-09-24
ES2771925T3 (es) 2020-07-07
HK1250914A1 (zh) 2019-01-18
IL255114B (en) 2022-04-01
SI3285803T1 (sl) 2020-02-28
RU2017140789A3 (zh) 2019-05-24
EP3285803B1 (en) 2019-12-18
EP3285803A1 (en) 2018-02-28
KR102464415B1 (ko) 2022-11-04
ZA201707179B (en) 2020-01-29
US11466090B2 (en) 2022-10-11
KR20180002711A (ko) 2018-01-08
PT3285803T (pt) 2020-02-18
HUE048528T2 (hu) 2020-07-28
CN108156814B (zh) 2021-07-09
JO3559B1 (ar) 2020-07-05
MA51815A (fr) 2020-12-23
RS59912B1 (sr) 2020-03-31
US20160311913A1 (en) 2016-10-27
AU2015392215B2 (en) 2022-04-07
JOP20200116A1 (ar) 2017-06-16
JP2020143115A (ja) 2020-09-10
CY1123211T1 (el) 2021-12-31
LT3285803T (lt) 2020-02-10
BR112017022772A2 (pt) 2018-07-31
IL291153A (en) 2022-05-01
SG10202004282RA (en) 2020-06-29
CA2984254A1 (en) 2016-10-27
CN113908268A (zh) 2022-01-11
JP2022126724A (ja) 2022-08-30

Similar Documents

Publication Publication Date Title
IL291153A (en) Methods for treating or preventing migraine headaches
EP3500289A4 (en) METHODS OF TREATING TRACHEOBRONCHOMALACIA
EP3288382A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP3113736A4 (en) Method for treatment of migraine and other headaches
IL265335A (en) Treating cluster headache
EP3286311A4 (en) Method for the treatment of malignancies
EP3171878A4 (en) Methods for treating paramyxoviruses
EP3229808A4 (en) Methods for treating fungal infections
EP3226967A4 (en) Methods and systems for preventative migraine headache treatment
EP3110509A4 (en) Method for treating cancer
EP3220916A4 (en) Method for treating cancer
EP3206688A4 (en) Method for treating cancer
EP3341080A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP3389634A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP3242947A4 (en) Method for the treatment of malignancies
EP3484515A4 (en) METHOD FOR TREATING FIBROSE
EP3389652A4 (en) METHODS OF TREATING CANCER
EP3154546A4 (en) Methods for treating pruritus
EP3448365A4 (en) CONSTIPATION TREATMENT METHOD
EP3334432A4 (en) CERDULATINIB FOR THE TREATMENT OF MYELOMA
EP3260119A4 (en) Combination method for treating cancer
EP3194025A4 (en) Methods for preventing or treating osteoarthritis
EP3247376A4 (en) Method for treating cancer
AU2015305430B2 (en) Method for treating hyperhidrosis
EP3250218A4 (en) Methods for treating obesity